Therapeutic Options for Continuous Dopaminergic Stimulation in Parkinson's Disease
Identifieur interne : 000D99 ( Ncbi/Curation ); précédent : 000D98; suivant : 000E00Therapeutic Options for Continuous Dopaminergic Stimulation in Parkinson's Disease
Auteurs : O. K. Sujith ; Carol LaneSource :
- Therapeutic Advances in Neurological Disorders [ 1756-2856 ] ; 2009.
Abstract
Treatment of Parkinson's disease aims to replace dopaminergic transmission at striatal synapses. In the normal state, nigral neurons fire continuously, exposing striatal dopamine receptors to relatively constant levels of dopamine. In the disease state, periodic dosing and the short half-life of antiparkinsonian drugs leads to more intermittent stimulation. Abnormal pulsatile stimulation of striatal dopamine receptors may lead to dysregulation of genes and proteins in downstream neurons and consequently, alterations in neuronal firing patterns. This may ultimately lead to motor complications. In order to prevent the development of motor complications a therapy that provides continuous dopaminergic stimulation as observed in the normal state would be ideal. Different routes of administration of levodopa and other dopaminergic drugs have been tried to achieve continuous dopaminergic stimulation (CDS). This review discusses the various methods available to achieve this goal with particular emphasis on duodenal dopa administration.
Url:
DOI: 10.1177/1756285608101378
PubMed: 21180645
PubMed Central: 3002621
Links toward previous steps (curation, corpus...)
- to stream Pmc, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000B97
- to stream Pmc, to step Curation: Pour aller vers cette notice dans l'étape Curation :000B97
- to stream Pmc, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A82
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000D99
Links to Exploration step
PMC:3002621Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Options for Continuous Dopaminergic Stimulation in
Parkinson's Disease</title><author><name sortKey="Sujith, O K" sort="Sujith, O K" uniqKey="Sujith O" first="O. K." last="Sujith">O. K. Sujith</name></author><author><name sortKey="Lane, Carol" sort="Lane, Carol" uniqKey="Lane C" first="Carol" last="Lane">Carol Lane</name></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">21180645</idno><idno type="pmc">3002621</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3002621</idno><idno type="RBID">PMC:3002621</idno><idno type="doi">10.1177/1756285608101378</idno><date when="2009">2009</date><idno type="wicri:Area/Pmc/Corpus">000B97</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000B97</idno><idno type="wicri:Area/Pmc/Curation">000B97</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Curation">000B97</idno><idno type="wicri:Area/Pmc/Checkpoint">000A82</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Checkpoint">000A82</idno><idno type="wicri:Area/Ncbi/Merge">000D99</idno><idno type="wicri:Area/Ncbi/Curation">000D99</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Therapeutic Options for Continuous Dopaminergic Stimulation in
Parkinson's Disease</title><author><name sortKey="Sujith, O K" sort="Sujith, O K" uniqKey="Sujith O" first="O. K." last="Sujith">O. K. Sujith</name></author><author><name sortKey="Lane, Carol" sort="Lane, Carol" uniqKey="Lane C" first="Carol" last="Lane">Carol Lane</name></author></analytic><series><title level="j">Therapeutic Advances in Neurological Disorders</title><idno type="ISSN">1756-2856</idno><idno type="eISSN">1756-2864</idno><imprint><date when="2009">2009</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>Treatment of Parkinson's disease aims to replace dopaminergic
transmission at striatal synapses. In the normal state, nigral neurons fire
continuously, exposing striatal dopamine receptors to relatively constant levels
of dopamine. In the disease state, periodic dosing and the short half-life of
antiparkinsonian drugs leads to more intermittent stimulation. Abnormal
pulsatile stimulation of striatal dopamine receptors may lead to dysregulation
of genes and proteins in downstream neurons and consequently, alterations in
neuronal firing patterns. This may ultimately lead to motor complications. In
order to prevent the development of motor complications a therapy that provides
continuous dopaminergic stimulation as observed in the normal state would be
ideal. Different routes of administration of levodopa and other dopaminergic
drugs have been tried to achieve continuous dopaminergic stimulation (CDS). This
review discusses the various methods available to achieve this goal with
particular emphasis on duodenal dopa administration.</p></div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D99 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 000D99 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= PMC:3002621
|texte= Therapeutic Options for Continuous Dopaminergic Stimulation in
Parkinson's Disease
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:21180645" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |